Evaluating Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis
Enrolling By Invitation
18-99 years
All
Phase
2
5 participants needed
1 Location
Brief description of study
The purpose of this study is to evaluate how well the study drug (Navitoclax) works in combination with ruxolitinib when compared to best available therapy in subjects with Relapsed/Refractory Myelofibrosis.
Detailed description of study
Duration: weekly visits for the first three weeks, every 2 weeks for visits for the next two months, then monthly visits for the next 4 months, and every 12 weeks thereafter until discontinuation from the study treatment.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Myelofibrosis
-
Age: Between 18 Years - 99 Years
-
Gender: All
Subjects will be recruited for this study from the physician practices of Penn Medicine. Subjects ≥ 18 years of age Documented Diagnosis of PMF
Updated on
01 Aug 2024.
Study ID: 850233
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
